Evidence map›Paper›PMID 40042503›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2025

Circulating proteomic biomarkers for cerebral amyloid angiopathy screening and risk stratification.

Jiajie Xu, Ya Su, Yuhui Sha, Jiayu Fu, Tingmeng Yan, Feifan Xu, Han Tang, Yunqing Ying, Yiwei Xia, Qiang Dong and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Circulating proteomic biomarkers for cerebral amyloid angiopathy screening and risk stratification.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Jiajie XuDepartment of Neurology, National Center for Neurological Disorders, National Clinical Research Centre for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai, P. R. China.ORCID 0000-0001-6819-4487
Ya SuDepartment of Neurology, National Center for Neurological Disorders, National Clinical Research Centre for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai, P. R. China.
Yuhui ShaDepartment of Neurology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P. R. China.
Jiayu FuDepartment of Neurology, National Center for Neurological Disorders, National Clinical Research Centre for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai, P. R. China.
Tingmeng YanDepartment of Neurology, National Center for Neurological Disorders, National Clinical Research Centre for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai, P. R. China.
Feifan XuDepartment of Neurology, National Center for Neurological Disorders, National Clinical Research Centre for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai, P. R. China.
Han TangDepartment of Neurology, National Center for Neurological Disorders, National Clinical Research Centre for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai, P. R. China.
Yunqing YingDepartment of Neurology, National Center for Neurological Disorders, National Clinical Research Centre for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai, P. R. China.
Yiwei XiaDepartment of Neurology, National Center for Neurological Disorders, National Clinical Research Centre for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai, P. R. China.
Qiang DongDepartment of Neurology, National Center for Neurological Disorders, National Clinical Research Centre for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai, P. R. China.
M Edip GurolJ Philip Kistler Stroke Research Center, Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts, USA.
Jun NiDepartment of Neurology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P. R. China.
Xin ChengDepartment of Neurology, National Center for Neurological Disorders, National Clinical Research Centre for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai, P. R. China.ORCID 0000-0001-7816-0547

Funding

Brain Science and Brain Diseases Youth Innovation Program of Shanghai Zhou Liangfu Medical Development FoundationCAMS Innovation Fund for Medical Sciences (CIFMS) 2024-I2M-C&T-B-007National Natural Science Foundation of China 81971123National Natural Science Foundation of China 82201467Noncommunicable Chronic Diseases-National Science and Technology Major Project 2023ZD0504903Sailing Program of Shanghai Science and Technology Committee 22YF1405500Shanghai Municipal Health Commission 2022XD022Shanghai "Rising Stars of Medical Talents" Youth Development Program SHWSRS (2023)_062
6 · The paper itself

Abstract

introductionWe systematically characterized plasma protein profiles in cerebral amyloid angiopathy (CAA) using proteomics and identified a hub protein panel for disease diagnosis and risk stratification.

methodsA total of 146 patients with probable CAA and 128 community-dwelling controls were prospectively enrolled. Plasma samples underwent proteomic analysis, and the hub proteins were validated in two validation cohorts. Machine learning algorithms were applied to construct and validate the performance of the circulating panel.

resultsWe identified 166 differentially expressed proteins in patients with CAA. Six hub proteins were selected to form the circulating panel, demonstrating excellent performance to distinguish patients from controls in all cohorts. Additionally, the risk stratification system derived from the hub protein panel accurately identified patients at high risk for new-onset lobar intracerebral hemorrhage. DISCUSSION: Our findings revealed distinctive circulating protein signatures in CAA and established a validated hub protein panel aiding in CAA screening and risk stratification. HIGHLIGHTS: We identified plasma protein signatures in CAA using proteomics. A circulating hub protein panel was developed and validated, demonstrating high accuracy for disease screening. The hub protein panel effectively stratified CAA patients according to risk of future intracerebral hemorrhage. The circulating panel offers potential for CAA screening and risk stratification.

Indexed as

Cerebral Amyloid AngiopathyProteomicsAgedAged, 80 and overBiomarkersFemaleHumansMaleMiddle AgedProspective StudiesRisk AssessmentBiomarkerscerebral amyloid angiopathydisease screeningmachine learning algorithmplasma biomarkerproteomic analysisrisk stratification

Identifiers

PMID40042503
PMCPMC11881623

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.